Strategic Signals Weekly

Atara Biotherapeutics, Inc. announced a regulatory update regarding its drug EBVALLO™. The company held a Type A meeting with the FDA to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the EBVALLO™ Biologics License Application.

Drug: EBVALLO™

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K. The company specified that this financial information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Enhabit, Inc. is providing supplemental disclosures to its proxy statement for the pending acquisition by Anchor Parent, LLC, an affiliate of Kinderhook Industries, LLC. This action addresses three stockholder lawsuits and demand letters alleging misrepresentations and omissions in the proxy statement regarding financial projections, valuation analyses, and conflicts of interest. The company aims to mitigate litigation risks and avoid delays to the merger, which is scheduled for a stockholder vote on May 12, 2026.

BioCryst Pharmaceuticals has entered into an exclusive license agreement with an Irish affiliate of Neopharmed Gentili S.p.A. for the commercialization of navenibart in Europe for hereditary angioedema. BioCryst will receive an upfront payment of $70 million, with potential for up to $275 million in future regulatory and sales milestone payments. Additionally, BioCryst will earn tiered royalties on net sales ranging from 18% to 30%.

Drug: navenibart · Indication: hereditary angioedema · Partner: Neopharmed Gentili S.p.A.

MacroGenics, Inc. amended its royalty purchase agreement with Sagard Healthcare Partners regarding global net sales of ZYNYZ (retifanlimab-dlwr). The company received an additional $60 million cash payment, bringing the total purchase price from Sagard to $130 million for the royalty rights. The amendment also revises Sagard's capped royalty interest and introduces a potential $20 million sales-based milestone payment for MacroGenics.

Drug: ZYNYZ (retifanlimab-dlwr) · Partner: Sagard Healthcare Partners

BridgeBio Pharma, Inc. entered into a new "at-the-market" (ATM) equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, allowing the company to sell up to $500 million of its common stock. This agreement, effective May 7, 2026, replaces a previous ATM agreement from May 2023. The company is not obligated to sell any shares, and the sales agents will receive a commission of up to 3.0% on gross proceeds.

Cellectar Biosciences, Inc. completed a registered direct offering and concurrent private placement, raising approximately $35 million in gross proceeds. The financing included common stock, pre-funded warrants, and milestone-based warrants, with funds earmarked to support the initiation of a Phase 3 trial for iopofosine I 131 in Waldenström macroglobulinemia.

Nektar Therapeutics entered into an at-the-market (ATM) equity distribution agreement with Guggenheim Securities and H.C. Wainwright & Co., enabling the company to offer and sell up to $150 million of common stock. Concurrently, Sandra Gardiner will retire as interim Chief Financial Officer, with Linda Rubinstein appointed as her successor, effective May 15, 2026.

Artiva Biotherapeutics, Inc. entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company expects to raise approximately $300.0 million in gross proceeds from the offering, before deducting underwriting discounts and expenses. The closing of the offering is anticipated on May 11, 2026.

Cytokinetics, Incorporated completed a public equity offering, issuing 9,859,155 shares of common stock at $71.00 per share. The underwriters fully exercised their option for an additional 1,478,873 shares. This offering resulted in net proceeds of approximately $760.2 million for the company.